ProCE Banner Activity


HCC: Current State, Available and Emerging Therapies – Episode 1

Podcast Episodes

This episode is the first of 2 podcasts based on a live presentation on treatment strategies and management of treatment-related adverse events for patients with hepatocellular carcinoma (HCC). Listen as 2 experts discuss the latest data supporting the optimal treatment of patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies, and the evolving treatment landscape in HCC.

To access episode 2, click here.

Physician Assistants: maximum of 0.50 hours of AAPA Category 1 CME credits Registered Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacology credit

Released: February 25, 2022

Expiration: February 24, 2023

No longer available for credit.



Bridget O’Brien

Bridget O’Brien, DNP, FNP-BC, AOCNP

Family Nurse Practitioner Program
Assistant Professor
Community, Systems, and Mental Health Nursing
Rush University
Nurse Practitioner
Department of Hematology/Oncology
Northwestern Medicine
Chicago, Illinois

Amit Singal

Amit Singal, MD, MS

Professor of Medicine
Medical Director of Liver Tumor Program
Chief of Hepatology
UT Southwestern Medical Center
Dallas, Texas

Mark Yarchoan

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland


This program is cosupported by educational grants from Bristol-Myers Squibb; Eisai; and Merck Sharp & Dohme Corp.

This activity is supported by educational grants from Eisai and Merck Sharp & Dohme Corp.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize current and emerging biomarkers and their impact on HCC treatment choice

  • Identify the roles of novel and emerging agents in the treatment of advanced HCC

  • Use recommended strategies to recognize and manage AEs associated with novel treatments for HCC


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.

Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.

Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. Listen to the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the post-test and evaluation form

The estimated time to complete this activity is 0.50 hours.

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 100%.

Release date: February 25, 2022
Expiration date: February 24, 2023




The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until February 24, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA Course Advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.